Unrecognized intrahepatic cholangiocarcinoma: An analysis of 993 adult cirrhotic liver explants

Clinical Transplantation

Volumn 27, Issue 3, 2013, Pages 403-409

  Vallin, Mélanie ^a   Sturm, Nathalie ^b   Lamblin, Géraldine ^c   Guillaud, Olivier ^a   Hilleret, Marie Noëlle ^b   Hervieu, Valérie ^a   Joubert, Juliette ^c   Abergel, Armand ^c   Leroy, Vincent ^b   Boillot, Olivier ^a   Dumortier, Jérôme ^a   Scoazec, Jean Yves ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b HÔPITAL MICHALLON   (France)

^c HÔTEL DIEU   (France)

Author keywords

Cholangiocarcinoma; Cirrhosis; Liver transplantation; Outcome; Recurrence; Survival

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; CYCLOSPORIN A; EVEROLIMUS; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ADULT; ARTICLE; BILE DUCT CARCINOMA; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; EXPLANT; FEMALE; HUMAN; HUMAN TISSUE; IATROGENIC DISEASE; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR BIOPSY; BILE DUCT TUMOR; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; COMPLICATION; DIFFERENTIAL DIAGNOSIS; FOLLOW UP; INTRAHEPATIC BILE DUCT; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RISK FACTOR;

ADULT; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 84878665053     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12108     Document Type: Article

References (21)

1. Khan SA, Toledano MB, Taylor-Robinson SD Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 2008: 10: 77.
2. Ferrell LD, Crawford JM, Dhillon AP, Scheuer PJ, Nakanuma Y Proposal for standardized criteria for the diagnosis of benign, borderline, and malignant hepatocellular lesions arising in chronic advanced liver disease. Am J Surg Pathol 1993: 17: 1113.
3. Bosman FT, Carneiro F, Hruban RH, Theise ND WHO Classification of Tumours of the Digestive System. Lyon: IARC Press, 2010.
4. Sorensen HT, Friis S, Olsen JH et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 1998: 28: 921.
5. Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005: 128: 620.
6. Shaib YH, El-Serag HB, Nooka AK et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol 2007: 102: 1016.
7. Kobayashi M, Ikeda K, Saitoh S et al. Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis. Cancer 2000: 88: 2471.
8. Rimola J, Forner A, Reig M et al. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology 2009: 50: 791.
9. Dumortier J, Lombard-Bohas C, Valette PJ et al. Needle tract recurrence of hepatocellular carcinoma after liver transplantation. Gut 2000: 47: 301.
10. Saborido BP, Diaz JC, de Los Galanes SJ et al. Does preoperative fine needle aspiration-biopsy produce tumor recurrence in patients following liver transplantation for hepatocellular carcinoma? Transplant Proc 2005: 37: 3874.
11. Yedibela S, Demir R, Zhang W, Meyer T, Hohenberger W, Schonleben F Surgical treatment of mass-forming intrahepatic cholangiocarcinoma: an 11-year Western single-center experience in 107 patients. Ann Surg Oncol 2009: 16: 404.
12. Shen WF, Zhong W, Xu F et al. Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma. World J Gastroenterol 2009: 15: 5976.
13. Zhou XD, Tang ZY, Fan J et al. Intrahepatic cholangiocarcinoma: report of 272 patients compared with 5, 829 patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2009: 135: 1073.
14. Sapisochin G, Fidelman N, Roberts JP, Yao FY Mixed hepatocellular-cholangiocarcinoma (HCC-CC) and intra-hepatic cholangiocarcinoma (I-CC) in patients transplanted for hepatocellular carcinoma. Liver Transpl 2011: 17: 934.
15. D'Amico F, Schwartz M, Vitale A et al. Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl 2009: 15: 1278.
16. Schwartz M, Roayaie S, Llovet J How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated? J Hepatol 2005: 43: 584.
17. Rosen CB, Heimbach JK, Gores GJ Liver transplantation for cholangiocarcinoma. Transpl Int 2010: 23: 692.
18. Becker NS, Rodriguez JA, Barshes NR, O'Mahony CA, Goss JA, Aloia TA Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period. J Gastrointest Surg 2008: 12: 117.
19. Ali JM, Bonomo L, Brais R et al. Outcomes and diagnostic challenges posed by incidental cholangiocarcinoma after liver transplantation. Transplantation 2011: 91: 1392.
20. Kneteman NM, Oberholzer J, Al Saghier M et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004: 10: 1301.
21. Vivarelli M, Dazzi A, Zanello M et al. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. Transplantation 2010: 89: 227.